Clinical Trials on Conditions or Focus of Study: B7-H3 Positive Relapsed/Advanced Malignant Solid Tumor in New Zealand

Total 82 results

Aadi Bioscience, Inc.

Recruiting

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

Malignant Solid Neoplasm | Neoplasms | Cancer | Neoplasm Metastasis | Solid Tumor | Metastatic Cancer | Metastasis | Advanced Solid Tumor | Metastatic Solid Tumor | Advanced Cancer | Tumor | Malignant Neoplasm | Malignant Tumor | Tumors | Cancer Metastatic | Tumor, Solid | Malignant Solid Tumor | TSC | TSC1 | TSC2 | Metastatic Neoplasm

Korea, Republic of, United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor

United States
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC; Seagen Inc.

Recruiting

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Locally Advanced or Metastatic Malignant Solid Tumors

United States, Japan, Canada
Novartis Pharmaceuticals

Completed

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3 | Squamous Lung Cancer With FGFR1 Amplification | Bladder Cancer With FGFR3 Mutation or Fusion | Advanced Solid Tumors With FGFR1 Amplication | Advanced Solid Tumors With FGFR2 Amplication | Advanced Solid Tumors With FGFR3 Mutation

France, Spain, Taiwan, Germany, Netherlands, Singapore, United States, Australia, Korea, Republic of, Thailand, Israel, Italy, Turkey, Austria
BeiGene

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Advanced Breast Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Non-small Cell Lung Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer | Hormone-receptor-positive...

Australia, United States
Altor BioScience

Completed

A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors

Malignant Solid Tumour | Locally Advanced Malignant Neoplasm

United States
Exicure, Inc.

Terminated

Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors

Advanced or Metastatic Solid Tumors | Advanced or Metastatic Merkel Cell Carcinoma | Advanced or Metastatic Cutaneous Squamous Cell Carcinoma | Advanced or Metastatic Melanoma | Advanced or Metastatic Head and Neck Squamous Cell Carcinoma

United States
Deciphera Pharmaceuticals LLC

Completed

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumor

United States
Roswell Park Cancer Institute
Novartis

Completed

Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer

Advanced Malignant Solid Neoplasm | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | ALK Positive

United States
AstraZeneca

Active, not recruiting

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Cervical Cancer | Ovarian Cancer | Pharmacokinetics | Endometrial Cancer | Pharmacodynamics | Safety and Tolerability | Advanced Solid Malignancy | Tumour Response | Advanced or Metastatic Breast Cancer | PIK3CA | AKT1 | PTEN | ER Positive | HER2 Positive

United States, Italy, Canada, France, Japan, United Kingdom, Spain, Netherlands, Denmark, Singapore
ABM Therapeutics Corporation

Recruiting

Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors.

Advanced Solid Tumor | RAS Mutation | NF1 Mutation | RAF Mutation

United States
Epizyme, Inc.

Completed

A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma

Synovial Sarcoma | Epithelioid Sarcoma | Renal Medullary Carcinoma | Malignant Rhabdoid Tumors (MRT) | Rhabdoid Tumors of the Kidney (RTK) | Atypical Teratoid Rhabdoid Tumors (ATRT) | Selected Tumors With Rhabdoid Features | INI1-negative Tumors | Malignant Rhabdoid Tumor of Ovary | Poorly Differentiated... and other conditions

France, United States, Australia, Taiwan, Belgium, United Kingdom, Canada, Germany, Italy
Erasca, Inc.

Recruiting

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations (SEACRAFT-1)

Advanced or Metastatic Solid Tumors

United States, Korea, Republic of, Canada, United Kingdom, Australia
National Cancer Institute (NCI)
Children's Oncology Group

Recruiting

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Malignant Solid Neoplasm | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico, Australia
NantCell, Inc.
Takeda

Terminated

QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas (GAMMA)

Cancer | Pancreatic Cancer | Advanced Solid Tumors | Metastatic Cancer | Bone Metastases | Solid Tumors | Pancreas Cancer | Adenocarcinoma of the Pancreas | Oncology | Cancer of Pancreas | Metastatic Pancreatic Cancer | Metastases | Cancer of the Pancreas | Advanced Malignancy | Oncology Patients | Endocrine Cancer

Italy, Spain, United Kingdom, Belgium, Canada, Denmark, Romania, United States, Germany, Netherlands, Korea, Republic of, Russian Federation, Australia, Austria, Lithuania, Portugal, Greece, Poland, Switzerland, Serbia, Bulgaria, ... and more
University Health Network, Toronto
Bayer; AstraZeneca; Amgen; AnHeart Therapeutics Inc.; Applied Health Research Centre and other collaborators

Recruiting

CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS) (CARMA-BROS)

Cancer | Malignancies Multiple | Malignant Solid Tumor | Cancer, Therapy-Related | Molecular Sequence Variation | Genetic Alteration | Gene Fusion | Receptor Tyrosine Kinase Gene Mutation | RTK Family Gene Mutation | Ras (Kras or Nras) Gene Mutation

Canada
National Cancer Institute (NCI)

Active, not recruiting

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent... and other conditions

United States, Puerto Rico
BeiGene
Myriad Genetics, Inc.

Completed

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

Spain, Australia, United States, United Kingdom
PMV Pharmaceuticals, Inc
Merck Sharp & Dohme LLC

Recruiting

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Metastatic Cancer | Advanced Solid Tumor | Endometrial Cancer | Metastatic Solid Tumor | Other Cancer | Advanced Malignant Neoplasm | Locally Advanced

United States, Spain, Korea, Republic of, Australia, France, Germany, Italy, Singapore, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary

Malignant Ovarian Epithelial Tumor | Ovarian Gynandroblastoma | Ovarian Sertoli-Leydig Cell Tumor | Ovarian Sex Cord Tumor With Annular Tubules | Ovarian Steroid Cell Tumor | Ovarian Granulosa Cell Tumor | Ovarian Sex Cord-Stromal Tumor | Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell...

United States
National Cancer Institute (NCI)

Active, not recruiting

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Malignant Glioma | Recurrent Childhood Ependymoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent... and other conditions

United States, Puerto Rico
Mirati Therapeutics Inc.

Recruiting

Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Pancreatic Adenocarcinoma | Solid Tumor | Non Small Cell Lung Cancer | Mesothelioma | Advanced Solid Tumor | Malignant Peripheral Nerve Sheath Tumors

United States
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Ann Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

Malignant Glioma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico
Pfizer

Terminated

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors

United States, Canada, United Kingdom, Korea, Republic of, Australia, Belgium, Denmark, Hungary, Russian Federation
National Cancer Institute (NCI)

Active, not recruiting

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Soft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma | Malignant Glioma | Ependymoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Rhabdomyosarcoma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Refractory Neuroblastoma | Refractory Non-Hodgkin Lymphoma and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Malignant Glioma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico, Australia, Canada
National Cancer Institute (NCI)

Active, not recruiting

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
Amgen

Terminated

Safety Study of AMG 228 to Treat Solid Tumors

Melanoma | Cancer | Colorectal Cancer | Advanced Solid Tumors | Squamous Cell Carcinoma of the Head and Neck | Non-small Cell Lung Cancer | Oncology | Tumors | Advanced Malignancy | Oncology Patients | Transitional Cell Carinoma of Bladder

Belgium, France, United States, Germany, Australia
Ascentage Pharma Group Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Melanoma | P53 Mutation | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Malignant Peripheral Nerve Sheath Tumors | MPNST | Unresectable or Metastatic Melanoma or Advanced Solid Tumors | MDM2 Gene Mutation

United States, Australia
AbbVie

Completed

ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors

Advanced Solid Tumors | Squamous Cell Carcinoma of the Head and Neck | Undifferentiated Pleomorphic Sarcoma | Carcinoma of the Breast

United States, France, Spain
Aminex Therapeutics, Inc.

Recruiting

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Melanoma | Cervical Cancer | Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Solid Tumor | Endometrial Cancer | Advanced Cancer | Diffuse Midline Glioma, H3 K27M-Mutant | Papillary Thyroid Cancer | Solid Carcinoma | Mesotheliomas Pleural | Glioma, Malignant | Ovary Cancer and other conditions

United States, Australia
IDEAYA Biosciences

Recruiting

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Breast Cancer | Ovarian Cancer | Prostate Cancer | Pancreas Cancer | Advanced or Metastatic Solid Tumors

United States
Ikena Oncology
Gilead Sciences

Terminated

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Breast Cancer | Head and Neck Cancer | Gynecologic Cancer | Colorectal Cancer | Pancreatic Cancer | Gastric Adenocarcinoma | Lung Adenocarcinoma | Advanced Solid Tumor

United States
Tempus AI
GlaxoSmithKline

Active, not recruiting

Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors (PAVO)

Melanoma | Head and Neck Cancer | Pancreatic Cancer | Esophageal Cancer | Solid Tumor | Metastatic Cancer | Endometrial Cancer | Urologic Cancer | Breast Tumor | Locally Advanced Solid Tumor | Lung Tumor | Colon Tumor, Malignant

United States
Fate Therapeutics

Terminated

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Melanoma | Lymphoma | Renal Cell Carcinoma | Cervical Cancer | Head and Neck Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | NSCLC | Advanced Solid Tumor | Small-cell Lung Cancer | HER2-positive Breast Cancer | Pancreas Cancer | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability and other conditions

United States
Fate Therapeutics

Completed

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Melanoma | Lymphoma | Renal Cell Carcinoma | Cervical Cancer | Head and Neck Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | NSCLC | Advanced Solid Tumors | HER2-positive Breast Cancer | Pancreas Cancer | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability and other conditions

United States
Leap Therapeutics, Inc.
Pfizer; Merck KGaA, Darmstadt, Germany

Terminated

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Solid Tumors | Advanced Triple Negative Breast Cancer | Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer | Advanced Metastatic Castration-Resistant Prostate Cancer | Advanced Platinum-Resistant Ovarian Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

HIV Infection | Hepatocellular Carcinoma | Non-Hodgkin Lymphoma | Metastatic Lung Non-Small Cell Carcinoma | Metastatic Melanoma | Kaposi Sarcoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable... and other conditions

United States
Medicenna Therapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)

Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions

United States, Australia, Korea, Republic of, Canada
Synthekine

Recruiting

Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors

Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Microsatellite Instability High | Malignant Melanoma | GastroEsophageal Cancer | Mismatch Repair Deficiency

United States
MacroGenics

Completed

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Cervical Cancer | Hematologic Neoplasms | Ovarian Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Small-cell Lung Cancer | TNBC - Triple-Negative Breast Cancer | HER2-positive Advanced Solid Tumors

Hong Kong, United States, Thailand, Australia, Spain, Bulgaria, Poland, Ukraine
Five Prime Therapeutics, Inc.
Bristol-Myers Squibb

Completed

Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)

Renal Cell Carcinoma | Head and Neck Cancer | Pancreatic Cancer | Ovarian Cancer | Malignant Glioma | Advanced Solid Tumors | Non-small Cell Lung Cancer

United States
NextCure, Inc.

Terminated

A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors

Breast Cancer | Ovarian Cancer | Non-small Cell Lung Cancer | Advanced or Metastatic Solid Tumors

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Recruiting

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Cervical Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Renal Pelvis Cancer | Urinary Bladder Neoplasm | Recurrent...

United States
NextCure, Inc.

Completed

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

Melanoma | Breast Cancer | Lung Cancer | Cholangiocarcinoma | Endometrial Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Advanced or Metastatic Solid Tumors | CRC

United States
National Cancer Institute (NCI)

Active, not recruiting

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Soft Tissue Sarcoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Osteosarcoma | Ewing Sarcoma | Recurrent Renal Cell Carcinoma | Refractory Malignant Solid Neoplasm | Rhabdomyosarcoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Malignant Solid Neoplasm | Recurrent Osteosarcoma | Recurrent... and other conditions

United States

Clinical Trials on Conditions or Focus of Study: B7-H3 Positive Relapsed/Advanced Malignant Solid Tumor in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations